AstraZeneca/Actavis Antibiotic Faces Limited Indication
This article was originally published in The Pink Sheet Daily
FDA allowed flexibility in AstraZeneca/Actavis’ gram-negative antibiotic development program, but agency’s advisory committee briefing documents propose more restrictive label than companies are seeking.
You may also be interested in...
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.
Final guidance excludes stool banks, putting in place more limited enforcement discretion regarding the requirement of an investigational new drug application for use of fecal transplants to treat C. diff infections, likely paving way for shift to any FDA-approved product.